Matinas BioPharma Holdings (MTNB) Total Non-Current Liabilities (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Total Non-Current Liabilities of $726000.0 for Q1 2026, down 79.32% year-over-year from $3.5 million in Q1 2025, and down 20.66% quarter-over-quarter from $915000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Total Non-Current Liabilities for 12 consecutive years, with $726000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 79.32% year-over-year to $726000.0; the TTM figure through Mar 2026 stood at $726000.0 (down 79.32% YoY), while the FY2025 annual figure was $915000.0, down 61.64% from the prior year.
- Total Non-Current Liabilities eased to $726000.0 in Q1 2026 per MTNB's latest filing, from $915000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $4.3 million in Q1 2022 and bottomed at $726000.0 in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $3.0 million across 5 years, with a median of $3.2 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities increased 21.31% — and 2026, when it sank 79.32%.
- Matinas BioPharma Holdings' Total Non-Current Liabilities stood at $3.9 million in 2022, then fell by 16.94% to $3.2 million in 2023, then retreated by 26.3% to $2.4 million in 2024, then plunged by 61.64% to $915000.0 in 2025, then declined by 20.66% to $726000.0 in 2026.
- Business Quant data shows MTNB's Total Non-Current Liabilities at $726000.0 in Q1 2026, $915000.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 262,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 262,000.00 |
| Mar 31, 2026 | 726,000.00 |
| Dec 31, 2025 | 915,000.00 |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 3.05 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.41 Mn |
| Jun 30, 2023 | 3.58 Mn |
| Mar 31, 2023 | 3.74 Mn |
| Dec 31, 2022 | 3.90 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 4.18 Mn |
| Mar 31, 2022 | 4.33 Mn |
| Dec 31, 2021 | 4.48 Mn |
| Sep 30, 2021 | 4.63 Mn |